Provider of liquid biopsy tests using CTCs. The flagship system uses a capture bed coated with specific antibodies to capture and separate CTCs from blood samples for analysis. The system has been clinically validated for pancreatic cancer, colorectal cancer, ovarian cancer, and breast cancer. The company was founded in 2007 and headquartered in Chapel Hill, United States. It has raised $18.1M in series b funding, with backing from Mizzou, NIH, HHS. The company operates in the Life Sciences - Oncology, Life Sciences - Clinical Genomics, Life Sciences - Genomics space. Its offerings span Oncology - In-Vitro Diagnostic Tests - Blood Cancer.
← All startups
Biofluidica
Series BProvider of liquid biopsy tests using CTCs. The flagship system uses a capture bed coated with specific antibodies to capture and separate CTCs from blood samples for analysis. The system has been clinically validated for pancreatic cancer, colorectal cancer, ovarian cancer, and breast cancer. The company was founded in 2007 and headquartered in Chapel Hill, United States. It has raised $18.1M in series b funding,…
About
Business model
Oncology > In-Vitro Diagnostic Tests > Blood Cancer,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Liquid Biopsy > DNA
Institutional investors
MizzouNIHHHS
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ Full list of active funds — filter by stage, check size, and geography.